357998
Position
President and CEO
Company
Decibel Therapeutics
Location
Boston Boston UNITED STATES
Bio
Steven Holtzman joined Decibel as president and chief executive officer in 2016. Steve brings more than 30 years of strategic, operational and leadership experience in the biotechnology industry. Prior to Decibel, he served as executive vice president, corporate development at Biogen, Inc., where he created and led the program leadership and management group through eight new drug approvals. He also led the business development and M&A group through successful completion of numerous transactions. Prior to Biogen, Steve served as the founder, chief executive officer and chair of the board of directors of Infinity Pharmaceuticals, Inc., a cancer drug discovery and development company. He was also an early leader and the chief business officer of Millennium Pharmaceuticals (now Takeda Oncology), a pioneer in large scale genetics and genomics, and was a founder, member of the board and the executive vice president of DNX Corporation, the first transgenic animal company. Steve is a member of the boards of directors of Visterra, Humatics, The Sync Project and Molecular Partners. In the not-for-profit arena, Steve is currently a trustee of the Berklee College of Music and previously served as the vice chairman of the board of trustees of the Hastings Center for Ethics and the Life Sciences. From 1996 to 2001, he served as a Presidential appointee to the U.S. National Bioethics Advisory Commission. Steve received his B.A. in philosophy from Michigan State University and his B.Phil. graduate degree in philosophy from Corpus Christi College, Oxford University, which he attended as a Rhodes Scholar.